Entity Central Index Key Cash and cash equivalent gross unrealized gain. Cash and cash equivalent gross unrealized loss. Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Title of 12(b) Security Security12b Title Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Shell Company Entity Shell Company Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Accrued clinical expenses, current. Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities - short-term Available For Sale Securities Debt Securities Current Accounts receivable from collaborations Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Marketable securities - long-term Available For Sale Securities Debt Securities Noncurrent Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use (ROU) assets Operating Lease Right Of Use Asset Other assets Other Assets Noncurrent Indefinite-lived intangible asset Indefinite Lived Intangible Assets Excluding Goodwill Goodwill Goodwill Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued clinical expenses Accrued Clinical Expenses Current Other accrued expenses Other Accrued Liabilities Current Operating lease liabilities - short-term Operating Lease Liability Current Total current liabilities Liabilities Current Deferred tax liabilities Deferred Income Tax Liabilities Net Deferred revenue Contract With Customer Liability Noncurrent Operating lease liabilities - long-term Operating Lease Liability Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders' equity Stockholders Equity [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding Preferred Stock Value Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 47,077,052 and 34,026,680 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Collaboration revenue Revenue From Contract With Customer Including Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income: Nonoperating Income Expense [Abstract] Interest and other income, net Interest Income Other Total other income Nonoperating Income Expense Net loss Net Income Loss Other comprehensive (loss) income Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Unrealized (loss) gain on marketable securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Weighted average common shares outstanding, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Accretion and amortization of investments In marketable debt securities. Represent non cash rent expense. Increase (decrease) in accrued clinical expenses. Increase decrease in operating lease liabilities. Proceeds from issuance of common stock under employee stock purchase plan. Remeasurement of lease liabilities arising from modification of right of use assets. Statement Of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Stock-based compensation Share Based Compensation Net accretion and amortization of investments in marketable debt securities Accretion And Amortization Of Investments In Marketable Debt Securities Non-cash rent expense Noncash Rent Expense Loss on disposal of fixed assets Gain Loss On Disposition Of Assets1 Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable from collaboration Increase Decrease In Accounts Receivable Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other assets Increase Decrease In Other Noncurrent Assets Accounts payable Increase Decrease In Accounts Payable Accrued clinical expenses Increase Decrease In Accrued Clinical Expenses Other accrued expenses Increase Decrease In Other Accrued Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Operating lease liabilities Increase Decrease In Operating Lease Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Proceeds from sale of property and equipment Proceeds From Sale Of Property Plant And Equipment Purchases of marketable securities Payments To Acquire Available For Sale Securities Debt Proceeds from maturities of marketable securities Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities Proceeds from sale of marketable securities Proceeds From Sale Of Available For Sale Securities Debt Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from the exercise of stock options Proceeds From Stock Options Exercised Proceeds from the issuance of common stock under Employee Stock Purchase Plan (ESPP) Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan Proceeds from sale of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents at the beginning of the period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents at the end of the period Supplemental non-cash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Operating lease liabilities arising from obtaining ROU assets Right Of Use Asset Obtained In Exchange For Operating Lease Liability Remeasurement of lease liabilities arising from modification of ROU assets Remeasurement Of Lease Liabilities Arising From Modification Of Right Of Use Assets Issuance of common stock upon cashless exercise of pre-funded warrants shares. Issuance of common stock upon cashless exercise of pre-funded warrants. Sale of common stock net of commissions and fees. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Balance Balance (in shares) Shares Outstanding Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs Stock Issued During Period Value New Issues Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs (in shares) Stock Issued During Period Shares New Issues Sale of common stock, net of commissions and fees Sale Of Common Stock Net Of Commissions And Fees Sale of common stock shares net of commissions and fees. Sale of common stock, net of commissions and fees (in shares) Sale Of Common Stock Shares Net Of Commissions And Fees Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of stock options ( in shares ) Stock Issued During Period Shares Stock Options Exercised Issuance of common stock under ESPP Stock Issued During Period Value Employee Stock Ownership Plan Issuance of common stock under ESPP (in shares) Stock Issued During Period Shares Employee Stock Ownership Plan Issuance of common stock for settlement of restricted stock units (RSUs) Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Issuance of shares of common stock for settlement of restricted stock units (RSUs) (in shares) Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Issuance of common stock upon cashless exercise of pre-funded warrants Issuance Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Issuance of common stock upon cashless exercise of pre-funded warrants (in shares) Issuance Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Shares Settlement of RSUs for cash Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition Unrealized gain (loss) on marketable debt securities Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Net income (loss) Balance Balance (in shares) Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Business Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies and Recent Accounting Pronouncements Significant Accounting Policies [Text Block] Fair value measurements and investments in marketable securities. Investments Debt And Equity Securities [Abstract] Fair Value Measurements and Investments in Marketable Securities Fair Value Measurements And Investments In Marketable Securities [Text Block] Payables And Accruals [Abstract] Other Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Restructuring And Related Activities [Abstract] Restructurings Restructuring And Related Activities Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock Plans and Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Collaborative and License Arrangement Disclosure. Collaboration Agreement Collaboration Agreement [Abstract] Collaboration Agreements Collaborative And License Arrangement Disclosure [Text Block] Milestones and Research Agreements Milestones and Research Agreements Milestones And Research Agreements [Abstract] Milestones and Research Agreements Milestones And Research Agreements [Text Block] Lease Cost [Abstract] Leases Lessee Operating Leases [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Other risks and uncertainties. Other Risks and Uncertainties Other Risks And Uncertainties Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Net Loss per Share Earnings Per Share Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Investments in Marketable Securities Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Schedule of Fair Value of Financial Assets Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block] Schedule of Other Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Summary of Restructuring Costs Schedule Of Restructuring And Related Costs [Text Block] Schedule of restructuring charges. Schedule of Restructuring Charges Schedule Of Restructuring Charges Table [Text Block] Schedule of accrued restructuring charges. Schedule of Accrued Restructuring Charges Schedule Of Accrued Restructuring Charges Table [Text Block] Summary of Warrants to Purchase Shares of Company's Common Stock Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Summary of Stock Option Activity and Related Information Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Stock Units and Related Information Nonvested Restricted Stock Shares Activity Table [Text Block] Summary of Assumptions Used to Estimate Fair Values of Stock Options Grants Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of Recognized Stock-Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Changes in Contract Liabilities Contract With Customer Asset And Liability Table [Text Block] Schedule of Quantitative Information of Operating Leases Lease Cost Table [Text Block] Schedule of Maturities Operating Lease Liabilities Lessee Operating Lease Liability Maturity Table [Text Block] Operating segments (in segments) Number Of Operating Segments Represents the number of approved products. FDA approved products (in products) Number Of Approved Products Number of warrants exercised. Significant accounting policies. Significant accounting policies. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] PublicOffering Public Offering Public Offering [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] ASU 2020-10 Accounting Standards Update202010 [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Number of shares sold Number of pre-funded warrants sold to purchase of common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Pre-funded warrants exercisable price per share Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Number of warrants exercised Number Of Warrants Exercised Numerator: Net Income Loss [Abstract] Denominator: Weighted Average Number Of Shares Outstanding [Abstract] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Options Employee Stock Option [Member] Common stock subject to purchase under employee stock purchase program. Common stock subject to purchase under ESPP Common Stock Subject To Purchase Under Employee Stock Purchase Program [Member] RSUs Restricted Stock Units R S U [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Change in Accounting Principle, Accounting Standards Update, Adoption Date Change In Accounting Principle Accounting Standards Update Adoption Date Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change In Accounting Principle Accounting Standards Update Adopted Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change In Accounting Principle Accounting Standards Update Immaterial Effect Cash equivalents at carrying value and available for sale debt securities amortized cost. Cash equivalents at carrying value and available for sale debt securities gross unrealized gain. Cash equivalents at carrying value and available for sale debt securities gross unrealized loss. Cash equivalents at carrying value and available for sale debt securities estimated fair value. Schedule Of Available For Sale Securities [Table] Schedule Of Available For Sale Securities [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] U.S and foreign corporate debt securities Corporate Debt Securities [Member] U.S. and foreign commercial paper Commercial Paper [Member] Asset-backed securities Asset Backed Securities [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Cash equivalents Cash Equivalents [Member] Short-term marketable securities Short Term Investments [Member] Long term marketable securities. Long Term Marketable Securities Long Term Marketable Securities [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Money market fund Money Market Funds [Member] U.S. treasury securities U S Treasury Securities [Member] Investments in marketable securities: Schedule Of Available For Sale Securities [Line Items] Amortized Cost Gross Unrealized Gain Cash And Cash Equivalent Gross Unrealized Gain Gross Unrealized Loss Cash And Cash Equivalent Gross Unrealized Loss Fair Value Cash And Cash Equivalents Fair Value Disclosure Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Gross Unrealized Gain Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Gross Unrealized Loss Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Fair Value Amortized Cost Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost Gross Unrealized Gain Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain Gross Unrealized Loss Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss Fair Value Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value The contractual term to maturity of short-term marketable securities and long-term marketable securities held by the Company. Short-term and long-term marketable securities. Short-term and Long-term marketable securities Short Term And Long Term Marketable Securities [Member] Available for sale securities maturity term Available For Sale Securities Maturity Term Cash equivalents at fair value. Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] U.S and foreign corporate debt securities U S Government Agencies Debt Securities [Member] U.S. and foreign commercial paper. U.S. and foreign commercial paper U S And Foreign Commercial Paper [Member] Cash equivalents Cash Equivalents At Fair Value [Abstract] Cash equivalents Short-term marketable securities Short Term Investments [Abstract] Short-term marketable securities Long-term marketable securities Long Term Investments [Abstract] Total assets measured at fair value Assets Fair Value Disclosure Fair value assets between levels transfers amount. Fair value assets transfers between level 1, level 2 or level 3 Fair Value Assets Between Levels Transfers Amount Accrued restructuring charges current. Accrued expenses: Accrued Liabilities Current [Abstract] Accrued compensation Employee Related Liabilities Current Accrued restructuring charges Accrued Restructuring Charges Current Accrued professional fees and other Accrued Professional Fees Current Total accrued expenses Accrued Liabilities Current Restructuring and related cost incurred cost (benefit). Schedule Of Restructuring And Related Costs [Table] Schedule Of Restructuring And Related Costs [Table] Restructuring Type Restructuring Cost And Reserve [Axis] Type of Restructuring Type Of Restructuring [Domain] Employee severance and related benefits. Employee Severance and Related Benefits Employee Severance And Related Benefits [Member] Asset impairment and other costs. Asset Impairment and Other Costs Asset Impairment And Other Costs [Member] Restructuring Cost And Reserve [Line Items] Restructuring Cost And Reserve [Line Items] Restructuring costs incurred Restructuring And Related Cost Incurred Cost Benefit Cumulative restructuring costs incurred through September 30, 2021 Restructuring And Related Cost Cost Incurred To Date1 Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] General and Administrative General And Administrative Expense [Member] Restructuring charges Accrued balance as of December 31, 2020 Costs incurred Restructuring Charges Reductions for cash payments Payments For Restructuring Accrued balance as of September 30, 2021 Proceeds received from the sale of assets Restructuring charges for remaining payment obligations of leased equipment. Costs incurred for remaining payment obligations of leased equipment Restructuring Charges For Remaining Payment Obligations Of Leased Equipment Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Two thousand and twenty at the market offerings. 2020 At the Market Offerings Two Thousand And Twenty At The Market Offerings [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum Minimum [Member] Subsidiary Sale Of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] The value of common stock authorized to issue in a public offering. Initial public offering value of shares authorized Initial Public Offering Value Of Shares Authorized Number of shares sold Sale Of Stock Number Of Shares Issued In Transaction Net proceeds from the issuance of common stock through equity plans Proceeds From Issuance Initial Public Offering Class of warrant or right issuance dates. Class of warrant or right expiration dates. Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Warrants issued. Warrants Issued on December 16, 2019 Warrants Issued [Member] Issue date Class Of Warrant Or Right Issuance Dates Expiration date Class Of Warrant Or Right Expiration Dates Exercise Price per Share Number of warrants outstanding Class Of Warrant Or Right Outstanding Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Employee Stock Purchase Plan Employee Stock [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Chief Executive Officer Executive Officer [Member] Employees including executive officers. Employees Including Executive Officers Employees Including Executive Officers [Member] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] TwoThousandEighteenEmployeeStockPurchasePlanMember 2018 ESPP Two Thousand Eighteen Employee Stock Purchase Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Shares reserved for issuance (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Option Indexed to Issuer's Equity, Type Option Indexed To Issuers Equity Type [Axis] Option Indexed to Issuer's Equity, Type Option Indexed To Issuers Equity Type [Domain] Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Options, Outstanding at beginning of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Option, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Option, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Option, Expired Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Option, Outstanding at end of period Options vested and exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted Average Exercise Price Per Share Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Options, Outstanding at beginning of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Option, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Option, Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Option, Expired Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price Option, Outstanding at end of period Options vested and exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Options Outstanding, Weighted Average Remaining Contractual Term (Years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Options Exercisable, Weighted Average Remaining Contractual Term (Years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Total Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Option, Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Options vested and exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Weighted-average grant-date fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Total intrinsic value of options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Options exercised Beginning of period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Ending of period Weighted Average Fair Value Per RSU at Grant Price Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value Roll Forward Beginning of period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Ending of period Represents the number of shares vested and subject to deferred settlement. Share based compensation arrangement by share based payment award equity instruments other than options vested in period subject to deferred settlement weighted average remaining contractual terms. Vested and subject to deferred settlement Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Subject To Deferred Settlement Weighted average remaining contractual term subject to deferred settlement Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Subject To Deferred Settlement Weighted Average Remaining Contractual Terms Total fair value of awards vested and settled Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value Total intrinsic value of awards vested and settled Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Forfeited Outstanding awards Total fair value of awards Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Amount Stock-based compensation expense Allocated Share Based Compensation Expense Number of common stock purchased by employees Stock Issued During Period Shares Employee Stock Purchase Plans Share based compensation arrangement fair value assumptions exercise price. Minimum Exercise price Share Based Compensation Arrangement Fair Value Assumptions Exercise Price Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Risk-free rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected term (years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Deferred Compensation Liability [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Compensation expense: Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Terminated Employees Employee Severance [Member] Wind- own of microbiome program. Wind-down of Microbiome Program Wind Down Of Microbiome Program [Member] Unrecognized stock-based compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Unrecognized stock-based compensation expense expected to be recognized, term Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Allergan agreement. Allergan Agreement Allergan Agreement [Member] BeiGene agreement. BeiGene Agreement Bei Gene Agreement [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Development and regulatory. Development and Regulatory Development And Regulatory [Member] Net sales milestone payments. Sales Milestone Payments Net Sales Milestone Payments [Member] BeiGene, Limited. Bei Gene Limited Bei Gene Limited [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Other Assets Other Noncurrent Assets [Member] Arbutus biopharma agreement. Arbutus Biopharma Agreement Arbutus Biopharma Agreement [Member] Antios agreement. Antios Agreement Antios Agreement [Member] Collaboration Agreements: Research And Development Arrangement Contract To Perform For Others [Line Items] Contract liability/deferred revenue Contract With Customer Liability Upfront cash payment received. Potential Milestone Payments. Agreed to pay maximum amount development and regulatory costs. Upfront cash payment received Upfront Cash Payment Received Potential milestone payments Potential Milestone Payments Agreed to pay maximum amount development and regulatory costs Agreed To Pay Maximum Amount Development And Regulatory Costs Contract with customer, liability, noncurrent Research and development expense Incremental costs. Incremental costs Incremental Costs Clinical trial collaboration costs incurred. Costs incurred Clinical Trial Collaboration Costs Incurred Contract with customer liability in additions. Contract with customer liability in deduction. Balance at Beginning of Period Additions Contract With Customer Liability In Additions Deductions Contract With Customer Liability In Deduction Balance at End of Period Performance milestone payment. Microbiome Targeted Colonic Delivery Program License Agreement Terms [Member] Door pharma agreement. Door Pharma Agreement Door Pharma Agreement [Member] Milestone and Research Agreements: Potential milestone payment Purchase Commitment Remaining Minimum Amount Committed Performance milestone payment Performance Milestone Payment Accrued expenses License agreement term. Up-front payments. Success-based milestones payment. Research and development funding charges. Milestone Payment. License agreement term License Agreement Term Up-front payment Up Front Payments Success-based milestones Success Based Milestones Payment Exercise and annual fees Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross Milestone payments Milestone Payment Research and development funding charges Research And Development Funding Charges Leases [Abstract] Operating lease, liability Operating Lease Liability Operating lease, ROU assets Lease cost Operating lease cost Operating Lease Cost Short-term lease cost Short Term Lease Cost Variable lease cost Variable Lease Cost Sublease income Sublease Income Total lease cost Lease Cost Operating cash flows from operating leases Operating Lease Payments ROU assets exchanged for new operating lease liabilities Weighted-average remaining lease term - operating leases Operating Lease Weighted Average Remaining Lease Term1 Weighted-average discount rate - operating leases Operating Lease Weighted Average Discount Rate Percent Three months ending December 31, 2021 Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Year Ending December 31, 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months Year Ending December 31, 2023 Lessee Operating Lease Liability Payments Due Year Two Year Ended December 31, 2024 Lessee Operating Lease Liability Payments Due Year Three Total Lessee Operating Lease Liability Payments Due Less: present value discount Lessee Operating Lease Liability Undiscounted Excess Amount Operating lease liabilities